Figure 2.

Ex vivo IFNγ ELISpots responses and B cell ELISpot responses 3 months following the second dose (16 weeks following the first dose) of the Sinopharm/BBIBP‐CorV vaccine. Ex vivo IFNγ ELISpots responses were measured to the S1 and S2 overlapping pool of peptides in 49 individuals between the age groups of 20–39 (n = 16), 40–59 (n = 21) and in ≥60 years olds (n = 12). There was no significant difference in the ex vivo ELISpot responses, for both S1 (p = .53) and S2 (p = .41) between the different age groups based on the Kruskal–Wallis test (A). The frequency of antibody secreting cells (ASCs) to S1, S2 and N recombinant proteins were assessed by B cell ELISpot assays in 20–39 (n = 8), 40–59 (n = 8), and in ≥60 years olds (n = 4). Significant differences in the responses to S1 (p = .01) and S2 (p = .03), but no difference to N (p = .22) in different age groups based on the Kruskal–Wallis test. The frequency of ASCs to the S1 protein significantly decreased with age (Spearman's r = −.57, p = .01), but not for S2 (Spearman's r = .37, p = .12) or N (Spearman's r = .34, p = .14) (C). IFNγ, interferon gamma